Compare SUVEN LIFE with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES NOVARTIS SUVEN LIFESCIENCES/
NOVARTIS
 
P/E (TTM) x 19.9 486.7 4.1% View Chart
P/BV x 4.0 28.2 14.3% View Chart
Dividend Yield % 0.5 1.6 32.3%  

Financials

 SUVEN LIFESCIENCES   NOVARTIS
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
NOVARTIS
Mar-18
SUVEN LIFESCIENCES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs338758 44.6%   
Low Rs169579 29.3%   
Sales per share (Unadj.) Rs52.1228.4 22.8%  
Earnings per share (Unadj.) Rs6.831.7 21.5%  
Cash flow per share (Unadj.) Rs8.632.8 26.2%  
Dividends per share (Unadj.) Rs1.5010.00 15.0%  
Dividend yield (eoy) %0.61.5 39.5%  
Book value per share (Unadj.) Rs65.3297.1 22.0%  
Shares outstanding (eoy) m127.2824.69 515.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.92.9 166.2%   
Avg P/E ratio x37.121.1 176.2%  
P/CF ratio (eoy) x29.620.4 145.0%  
Price / Book Value ratio x3.92.2 172.6%  
Dividend payout %22.031.5 69.7%   
Avg Mkt Cap Rs m32,27216,505 195.5%   
No. of employees `0001.10.7 162.0%   
Total wages/salary Rs m6611,445 45.7%   
Avg. sales/employee Rs Th6,132.28,441.3 72.6%   
Avg. wages/employee Rs Th611.12,163.6 28.2%   
Avg. net profit/employee Rs Th803.51,173.1 68.5%   
INCOME DATA
Net Sales Rs m6,6355,639 117.7%  
Other income Rs m2421,718 14.1%   
Total revenues Rs m6,8777,357 93.5%   
Gross profit Rs m1,604-63 -2,566.7%  
Depreciation Rs m22125 875.1%   
Interest Rs m3855 68.2%   
Profit before tax Rs m1,5871,575 100.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m718792 90.7%   
Profit after tax Rs m869784 111.0%  
Gross profit margin %24.2-1.1 -2,181.4%  
Effective tax rate %45.250.3 90.0%   
Net profit margin %13.113.9 94.3%  
BALANCE SHEET DATA
Current assets Rs m6,2329,522 65.5%   
Current liabilities Rs m1,4903,296 45.2%   
Net working cap to sales %71.5110.4 64.7%  
Current ratio x4.22.9 144.8%  
Inventory Days Days8637 236.1%  
Debtors Days Days8328 290.6%  
Net fixed assets Rs m4,04346 8,789.8%   
Share capital Rs m127123 103.2%   
"Free" reserves Rs m8,1837,213 113.4%   
Net worth Rs m8,3107,336 113.3%   
Long term debt Rs m180-   
Total assets Rs m10,38911,105 93.5%  
Interest coverage x43.129.5 146.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.5 125.8%   
Return on assets %8.77.6 115.6%  
Return on equity %10.510.7 98.0%  
Return on capital %19.522.2 87.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62261 9,276.8%   
Fx outflow Rs m1,7993,630 49.6%   
Net fx Rs m3,822-3,570 -107.1%   
CASH FLOW
From Operations Rs m3561,610 22.1%  
From Investments Rs m-279687 -40.6%  
From Financial Activity Rs m-225-2,677 8.4%  
Net Cashflow Rs m-148-380 39.0%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 2.0 -  
FIIs % 0.0 1.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 21.5 169.8%  
Shareholders   37,287 41,647 89.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

SUVEN LIFESCIENCES Surges by 6%; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

SUVEN LIFESCIENCES share price has surged by 6% and its current market price is Rs 284. The BSE HEALTHCARE is up by 0.5%. The top gainers in the BSE HEALTHCARE Index is SUVEN LIFESCIENCES (up 5.7%). The top losers are AJANTA PHARMA and CADILA HEALTHCARE .

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Oct 22, 2019 03:37 PM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS